- Page 1:
SCIENTIFIC REPORT 2010 - 2011 ISTIT
- Page 4 and 5:
Line 5 - Tumor Immunology and Innov
- Page 6 and 7:
This volume is the third edition of
- Page 9 and 10:
THE INSTITUTE THE INSTITUTE 9
- Page 11 and 12:
Aerial view of the Busonera area TH
- Page 13 and 14:
Chief Officer Address THE INSTITUTE
- Page 16 and 17:
The IOV Governance The IOV is gover
- Page 18 and 19:
GENERAL DIRECTORATE Pier Carlo Muzz
- Page 21 and 22:
Chief Medical Officer Report CLINIC
- Page 23 and 24:
to interact with other IRCCS to pro
- Page 25 and 26:
DRG average relative weight 4,5 4,0
- Page 27 and 28:
Radiation treatments 1200 1000 800
- Page 29 and 30:
The experts of these groups meet at
- Page 31 and 32:
THE DEPARTMENTS THE DEPARTMENTS 31
- Page 33 and 34:
Department of Clinical Oncology THE
- Page 35 and 36:
Clinical and Research Staff Vittori
- Page 37 and 38:
Clinical Activity Distribution of p
- Page 39 and 40:
Major Ongoing Research Projects NEw
- Page 41 and 42:
of Ramucirumab using a double-blind
- Page 43:
events has been planned in order to
- Page 46 and 47:
Main Pubblications Clinical Oncolog
- Page 48 and 49:
Mission The mission of this Unit is
- Page 50 and 51:
Major Ongoing Research Projects iDE
- Page 52:
NEw ThErapEuTiC STraTEGiES iN ThE T
- Page 55 and 56:
Clinical and Research Staff Antonio
- Page 57 and 58:
Department of Surgery THE DEPARTMEN
- Page 59 and 60:
Clinical and Research Staff Carlo C
- Page 61 and 62:
Major Research Collaborations Insid
- Page 64 and 65:
Main Pubblications Chief Breast Sur
- Page 66 and 67:
Mission The mission of the Breast S
- Page 68 and 69:
Main Pubblications Melanoma and Sof
- Page 70 and 71:
Mission The Melanoma and Soft Tissu
- Page 72 and 73:
National Collaborations Italian Sar
- Page 74 and 75:
express bioluminescent or fluoresce
- Page 76 and 77:
Diagnostic and Operative Endoscopy
- Page 78 and 79:
Mission The mission of the Unit is
- Page 80 and 81:
Major Ongoing Research Projects frO
- Page 82 and 83:
Main Pubblications Chief Comparison
- Page 85 and 86:
Mission The mission of the Unit of
- Page 87 and 88:
late (occurring after the first che
- Page 89 and 90:
Department of Imaging, Radiology &
- Page 91 and 92:
Clinical and Research Staff Fabio P
- Page 93 and 94:
Major Ongoing Research Projects Dif
- Page 96 and 97:
Main Pubblications Chief Correlatio
- Page 98 and 99:
Mission The Breast Imaging Unit mis
- Page 100 and 101:
Regarding the new HIBRC2 study, the
- Page 102 and 103:
Methods. Patient accrual, following
- Page 104 and 105:
Mission and Clinical Activity The m
- Page 107 and 108:
Department of Radiotherapy & Nuclea
- Page 109 and 110:
Clinical and Research Staff Guido S
- Page 111 and 112:
Clinical Activity The acquisition o
- Page 113 and 114:
Areas of Excellence Thyroid cancer
- Page 115 and 116:
Fig. 2. The thick Beryllium target,
- Page 117 and 118:
field and the Nuclear Medicine Serv
- Page 120 and 121:
Main Pubblications Chief Medical Ph
- Page 122 and 123:
Mission To assure safe, accurate an
- Page 124 and 125:
Other Programs and Future Perspecti
- Page 127 and 128:
Department of Experimental, Laborat
- Page 129 and 130:
Clinical and Research Staff Annaros
- Page 131 and 132:
Analyses for solid tumors by year A
- Page 133 and 134:
egard, the activity of some researc
- Page 135 and 136:
to high-risk families; b) assessmen
- Page 137 and 138:
with plasmids expressing either p16
- Page 139 and 140:
The results published so far indica
- Page 141 and 142:
levels of h-TERT mRNA increased wit
- Page 143 and 144:
More recently, given that the real
- Page 145 and 146:
aDvaNCED appliCaTiONS Of CirCulaTiN
- Page 147 and 148:
the persistence of more aggressive
- Page 149 and 150:
phosphokinome will be investigated
- Page 151 and 152:
algorithm that takes into account t
- Page 153 and 154:
samples. Except for 13q deletions,
- Page 155 and 156:
Clinical and Research Staff Giusepp
- Page 157 and 158:
Figure 1. the tumor of the adrenal
- Page 159 and 160:
goal of this project is to use a co
- Page 161 and 162:
Department of Services THE DEPARTME
- Page 163 and 164:
Clinical and Research Staff Angelo
- Page 165 and 166:
according to the onco-AIFA Registry
- Page 168 and 169:
Main Pubblications Chief Alberto Ba
- Page 170 and 171:
Mission This Unit is mainly devoted
- Page 172 and 173:
Main Pubblications Chief Positive e
- Page 174 and 175:
Mission The Psycho-oncology Service
- Page 176 and 177:
An ad hoc intervention has therefor
- Page 178 and 179:
Main Pubblications Chief Cancer pre
- Page 180 and 181:
Mission The main aims of the Veneto
- Page 182:
Population and Social Policies. Thi
- Page 187 and 188:
Scientific Director Address THE RES
- Page 189 and 190:
e transferred from the bench to bed
- Page 191 and 192:
Scientific Directorate Organization
- Page 193 and 194: library Responsible: Mauro Apostoli
- Page 195 and 196: In the awareness of the difficult t
- Page 197 and 198: Research: Input and Output The rese
- Page 199 and 200: strategic focus for the Government
- Page 201 and 202: Impact Factor Trend 1000 800 600 40
- Page 203 and 204: Clinical and Research Staff Gian Lu
- Page 205 and 206: International Collaborations Emma C
- Page 209 and 210: Strategic Scientific Options THE RE
- Page 211 and 212: approaches are tested at the IOV wi
- Page 213 and 214: Thiopurine S-methyltransferase (TPM
- Page 215 and 216: of specific functional features of
- Page 217 and 218: RESEARCH ACTIVITY REPORT RESEARCH A
- Page 219 and 220: N° Prog Titolo Responsabile L01P01
- Page 221 and 222: N° Prog Titolo Responsabile L02P01
- Page 223 and 224: N° Prog Titolo Responsabile L03P01
- Page 225 and 226: L03P44 L03P45 L03P46 L03P47 L03P48
- Page 227 and 228: N° Prog Titolo Responsabile L04P01
- Page 229 and 230: L04P39 Chemioterapia adiuvante in p
- Page 231 and 232: N° Prog Titolo Responsabile L05P01
- Page 233 and 234: Progr. Titolo Responsabile L06P01 L
- Page 235 and 236: CLINICAL RESEARCH CLINICAL RESEARCH
- Page 237 and 238: Numerous phase II and III, sponsore
- Page 239 and 240: A Multicenter phase III trial to ev
- Page 241 and 242: LUNG An International multicenter r
- Page 243: A randomized, double-blind, placebo
- Page 247 and 248: Ospedale classificato ed equiparato
- Page 249 and 250: EDUCATION EDUCATION 249
- Page 251 and 252: Integrative Oncology Care G. Opoche
- Page 253 and 254: Aggiornamento delle linee guida sul
- Page 255 and 256: DOCTOraTE SChOOl iN ONCOlOGy aND Su
- Page 257 and 258: 2009 Barbara Seliger How tumor cell
- Page 259: Genoveffa Franchini HTLV-1, the smo
- Page 263: Awards In November 2010 Dr. Giulia
- Page 266 and 267: 2009 PUBLICATIONS / Journals indexe
- Page 268 and 269: MGMT promoter methylation status. J
- Page 270 and 271: experience. Lung Cancer; 68:2; 228-
- Page 272 and 273: 98 Mandruzzato S, Solito S, Falisi
- Page 274 and 275: pathway biomarker. Clinical Colorec
- Page 276 and 277: ates of adrenal surgery: Analysis o
- Page 278 and 279: 17 Savastano S, Vecchiato M, Sarzo
- Page 280 and 281: from Italian cancer registries. Dig
- Page 282 and 283: of women with atypical squamous cel
- Page 284 and 285: a new approach to an old question.
- Page 286 and 287: 112 Mescoli C, Castoro C, Sergio A,
- Page 288 and 289: Investigators, Spurdle A B, Holland
- Page 290 and 291: surgery. Psycho-oncology; 20:7; 706
- Page 292 and 293: 2011 PUBLICATIONS / Journals indexe
- Page 294 and 295:
27 Castelblanco E, Gallel P, Ros S,
- Page 296 and 297:
children. Clinical and experimental
- Page 298 and 299:
U, Hogervorst F B, Kriege M, van de
- Page 300 and 301:
has stopped increasing. Epidemiolog
- Page 302 and 303:
137 Trojniak M P, Palozzo A C, Mazu
- Page 305 and 306:
INDEX INDEX 305
- Page 307 and 308:
Granziera Elisa 83, 86-87 Gregianin
- Page 309 and 310:
Immunotherapy 130, 133, 151, 200, 2
- Page 312:
April 2012